FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367596117> ?p ?o ?g. }

• W4367596117 endingPage "3544" @default.
• W4367596117 startingPage "3534" @default.
• W4367596117 abstract "PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response. RESULTS One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported. CONCLUSION The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS." @default.
• W4367596117 created "2023-05-02" @default.
• W4367596117 creator A5001370766 @default.
• W4367596117 creator A5003200344 @default.
• W4367596117 creator A5003401818 @default.
• W4367596117 creator A5003941928 @default.
• W4367596117 creator A5004923811 @default.
• W4367596117 creator A5005525451 @default.
• W4367596117 creator A5008348483 @default.
• W4367596117 creator A5024556674 @default.
• W4367596117 creator A5025797543 @default.
• W4367596117 creator A5026534937 @default.
• W4367596117 creator A5027493029 @default.
• W4367596117 creator A5027994767 @default.
• W4367596117 creator A5028677250 @default.
• W4367596117 creator A5033344593 @default.
• W4367596117 creator A5035746810 @default.
• W4367596117 creator A5036577994 @default.
• W4367596117 creator A5039057642 @default.
• W4367596117 creator A5045229290 @default.
• W4367596117 creator A5046827092 @default.
• W4367596117 creator A5046985332 @default.
• W4367596117 creator A5055773353 @default.
• W4367596117 creator A5056954410 @default.
• W4367596117 creator A5060196258 @default.
• W4367596117 creator A5065093182 @default.
• W4367596117 creator A5066028521 @default.
• W4367596117 creator A5070567455 @default.
• W4367596117 creator A5071978632 @default.
• W4367596117 creator A5072008697 @default.
• W4367596117 creator A5075026758 @default.
• W4367596117 creator A5080315299 @default.
• W4367596117 creator A5084340492 @default.
• W4367596117 creator A5087775013 @default.
• W4367596117 creator A5090009905 @default.
• W4367596117 date "2023-07-01" @default.
• W4367596117 modified "2023-10-13" @default.
• W4367596117 title "Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial" @default.
• W4367596117 cites W1980972742 @default.
• W4367596117 cites W2012686883 @default.
• W4367596117 cites W2031932184 @default.
• W4367596117 cites W2066465348 @default.
• W4367596117 cites W2068493370 @default.
• W4367596117 cites W2122395736 @default.
• W4367596117 cites W2158669800 @default.
• W4367596117 cites W2556415172 @default.
• W4367596117 cites W2559562829 @default.
• W4367596117 cites W2583102591 @default.
• W4367596117 cites W2608896188 @default.
• W4367596117 cites W2744415080 @default.
• W4367596117 cites W2764282137 @default.
• W4367596117 cites W2903319422 @default.
• W4367596117 cites W3003423609 @default.
• W4367596117 cites W3093817012 @default.
• W4367596117 cites W3198080127 @default.
• W4367596117 cites W3217154468 @default.
• W4367596117 cites W4200536979 @default.
• W4367596117 doi "https://doi.org/10.1200/jco.22.01935" @default.
• W4367596117 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37126762" @default.
• W4367596117 hasPublicationYear "2023" @default.
• W4367596117 type Work @default.
• W4367596117 citedByCount "5" @default.
• W4367596117 countsByYear W43675961172023 @default.
• W4367596117 crossrefType "journal-article" @default.
• W4367596117 hasAuthorship W4367596117A5001370766 @default.
• W4367596117 hasAuthorship W4367596117A5003200344 @default.
• W4367596117 hasAuthorship W4367596117A5003401818 @default.
• W4367596117 hasAuthorship W4367596117A5003941928 @default.
• W4367596117 hasAuthorship W4367596117A5004923811 @default.
• W4367596117 hasAuthorship W4367596117A5005525451 @default.
• W4367596117 hasAuthorship W4367596117A5008348483 @default.
• W4367596117 hasAuthorship W4367596117A5024556674 @default.
• W4367596117 hasAuthorship W4367596117A5025797543 @default.
• W4367596117 hasAuthorship W4367596117A5026534937 @default.
• W4367596117 hasAuthorship W4367596117A5027493029 @default.
• W4367596117 hasAuthorship W4367596117A5027994767 @default.
• W4367596117 hasAuthorship W4367596117A5028677250 @default.
• W4367596117 hasAuthorship W4367596117A5033344593 @default.
• W4367596117 hasAuthorship W4367596117A5035746810 @default.
• W4367596117 hasAuthorship W4367596117A5036577994 @default.
• W4367596117 hasAuthorship W4367596117A5039057642 @default.
• W4367596117 hasAuthorship W4367596117A5045229290 @default.
• W4367596117 hasAuthorship W4367596117A5046827092 @default.
• W4367596117 hasAuthorship W4367596117A5046985332 @default.
• W4367596117 hasAuthorship W4367596117A5055773353 @default.
• W4367596117 hasAuthorship W4367596117A5056954410 @default.
• W4367596117 hasAuthorship W4367596117A5060196258 @default.
• W4367596117 hasAuthorship W4367596117A5065093182 @default.
• W4367596117 hasAuthorship W4367596117A5066028521 @default.
• W4367596117 hasAuthorship W4367596117A5070567455 @default.
• W4367596117 hasAuthorship W4367596117A5071978632 @default.
• W4367596117 hasAuthorship W4367596117A5072008697 @default.
• W4367596117 hasAuthorship W4367596117A5075026758 @default.
• W4367596117 hasAuthorship W4367596117A5080315299 @default.
• W4367596117 hasAuthorship W4367596117A5084340492 @default.
• W4367596117 hasAuthorship W4367596117A5087775013 @default.
• W4367596117 hasAuthorship W4367596117A5090009905 @default.
• W4367596117 hasBestOaLocation W43675961171 @default.

• next